Close

GD2

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Product List Background Anti-GD2 CAR-T Services Anti-GD2 CAR-T In Vitro Assay ServicesAnti-GD2 CAR-T In Vivo Assay Services

Product List

Creative Biolabs is your trusted partner for anti-GD2 CAR-T therapy development. We provide a comprehensive range of products, such as anti-GD2 vectors, cells, and viral particles. Our team understands each researcher's needs and we also offer customized CAR-T cell development services tailored to your specific requirements.

Background

GD2 is known as ganglioside G2 or GRD2, which is used as a target for immunotherapy in patients with malignant melanoma and neuroblastoma. This protein is expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. Therefore, GD2 is associated with human neuroblastoma and melanoma. GD2-targeted immunotherapy has shown promising results in clinical trials for the treatment of melanoma and neuroblastoma patients.

Associated Diseases

Human neuroblastoma

Melanoma

Neuroblastoma

Others

Anti-GD2 CAR-T Services

Anti-GD2 CAR-T In Vitro Assays

Anti-GD2 CAR-T Expression Test

The anti-GD2 CAR-T expression test is designed to monitor the expression of the anti-GD2 CAR-T receptor and its components in T cells. At Creative Biolabs, we utilize diverse detection techniques such as flow cytometry, western blotting, and QPCR to analyze CAR expression.

Fig.1 Flow cytometry analysis of cell-surface expression of anti-GD2-CAR on transduced T cells. (Zhang, et al., 2023)Fig.1 Flow cytometry analysis of cell-surface expression of anti-GD2-CAR on transduced T cells.1

Anti-GD2 CAR-T Proliferation Test

To evaluate the ability of anti-GD2 CAR-T cells to proliferate and expand in response to specific stimuli, Creative Biolabs provides various methods for measuring CAR-T cell proliferation including flow cytometry analysis, cell counting, and colorimetric assays.

Fig.2 The proliferation analysis of the proliferation of anti-GD2-CAR, in combination with or without Nivolumab in vitro. (Zhang, et al., 2023)Fig.2 The proliferation analysis of the proliferation of anti-GD2-CAR, in combination with or without Nivolumab in vitro. The result showed the GD2-specific CAR-T could effectively proliferate.1

Anti-GD2 CAR-T Cytokine Release Test

Our comprehensive cytokine release test services detect a wide range of cytokines, including IL-2, TNF-α, and IFN-γ. There are several techniques available for quantifying the levels of released cytokines including ELISAs, ELISPOT, and multiplex bead array.

Fig.3 ELISA analysis of cytokine release (IFN-γ and TNF-α) in GD2 CAR-T cells co-cultured with various glioblastoma cell lines. (Zhang, et al., 2023)Fig.3 ELISA analysis of cytokine release (IFN-γ and TNF-α) in GD2 CAR-T cells co-cultured with various glioblastoma cell lines.1

Anti-GD2 CAR-T In Vitro Cytotoxicity Assay

We provide CAR-T cytotoxicity assays that enable researchers to determine the efficiency of anti-GD2 CAR-T cells in targeting and eliminating cancer cells expressing GD2.

Fig.4 The cytotoxicity of anti-GD2 CAR-T against various glioblastoma cell lines. (Zhang, et al., 2023)Fig.4 The cytotoxicity of anti-GD2 CAR-T against various glioblastoma cell lines. GD2 CAR-T cells exhibited antigen-specific cytotoxicity against GD2+ glioblastoma cells.1

Anti-GD2 CAR-T In Vivo Assays

Anti-GD2 CAR-T Cell Therapy Animal Models

We offer in vivo anti-GD2 CAR-T cell therapy testing services in animal models. Our animal models, including xenograft, humanized, syngeneic, and transgenic models, enable researchers to assess the therapeutic efficacy and safety of CAR-T cell therapies in vivo.

Fig.5 A schematic of in situ xenograft nude mouse model. (Wang, et al., 2020)Fig.5 A schematic of in situ xenograft nude mouse model.2

Efficacy Test of Anti-GD2 CAR-T

Creative Biolabs provide in vivo assays to test GD2 CAR-T cell efficacy and safety. These assays allow us to evaluate the ability of CAR-T cells to target and eliminate tumor cells, providing crucial information for assessing the efficacy of GD2 CAR-T cell therapy.

Fig.6 In vivo evaluation of the antitumor activity of anti-GD2 CAR-T. (Wang, et al., 2020)Fig.6 In vivo evaluation of the antitumor activity of anti-GD2 CAR-T. The results showed that GD2 CAR-T cells specifically eliminated tumors as measured by either bioluminescence (BLI).2

Toxicity Evaluation Anti-GD2 CAR-T

Furthermore, we recognize the importance of understanding the immune response generated by the anti-GD2 CAR T cell therapy. Therefore, we offer in vivo toxicity study services. These studies help to characterize potential side effects of the anti-GD2 CAR T cell therapy.

References

  1. Zhang, Guangji.; et al. "GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy." Translational Oncology 32 (2023): 101663.
  2. Wang, Kai.; et al. "GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision." Nature cancer 1.10 (2020): 990-997.
  • CAR Vector Products

  • AbTCR Vector Products

  • CAR Cell Products

  • CAR Viral Particles

  • TriCAR Vector Products

  • CAR-MA Vector Products

  • CAR-MA Cell Products

  • CAR Animal Cells

  • CAR mRNA

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
  • CAR Vector Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
XS-0822-YF8386 TS-Fluc Anti-Human GD2 scFv (XW-447) CD28-CD3ζ CAR, pCDCAR1 Human XW-447 Human 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8387 TS-Fluc Anti-Human GD2 scFv (XW-448) CD28-CD3ζ CAR, pCDCAR1 Human XW-448 Human 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8388 TS-Fluc Anti-Human GD2 scFv (XW-449) CD28-CD3ζ CAR, pCDCAR1 Human XW-449 Human 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8389 TS-Fluc Anti-Human GD2 scFv (XW-450) CD28-CD3ζ CAR, pCDCAR1 Human XW-450 Human 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8390 TS-Fluc Anti-Mouse GD2 scFv (XW-451) CD28-CD3ζ CAR, pCDCAR1 Mouse XW-451 Rat 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8391 TS-Fluc Anti-Human GD2 scFv (XW-452) CD28-CD3ζ CAR, pCDCAR1 Human XW-452 Mouse 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8392 TS-Fluc Anti-Human GD2 scFv (XW-453) CD28-CD3ζ CAR, pCDCAR1 Human XW-453 Humanized 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8393 TS-Fluc Anti-Human GD2 scFv (XW-454) CD28-CD3ζ CAR, pCDCAR1 Human XW-454 Mouse 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8394 TS-Fluc Anti-Human GD2 scFv (XW-455) CD28-CD3ζ CAR, pCDCAR1 Human XW-455 Mouse 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8395 TS-Fluc Anti-Human GD2 scFv (XW-456) CD28-CD3ζ CAR, pCDCAR1 Human XW-456 Mouse 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8396 TS-Fluc Anti-Human GD2 scFv (XW-457) CD28-CD3ζ CAR, pCDCAR1 Human XW-457 Humanized 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8397 TS-Fluc Anti-Human GD2 scFv (XW-458) CD28-CD3ζ CAR, pCDCAR1 Human XW-458 Mouse 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8398 TS-Fluc Anti-Human GD2 scFv (XW-459) CD28-CD3ζ CAR, pCDCAR1 Human XW-459 Mouse 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF8792 TS-Fluc Anti-Human GD2 scFv (XW-444) 41BB-CD3ζ CAR, pCDCAR1 Human XW-444 Humanized 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF9610 TS-IL15 SA Anti-Human GD2 scFv (XW-444) CD28-CD3ζ CAR, pCDCAR1 Human XW-444 Humanized 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF9611 TS-IL15 SA Anti-Human GD2 scFv (XW-445) CD28-CD3ζ CAR, pCDCAR1 Human XW-445 Human 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF9612 TS-IL15 SA Anti-Human GD2 scFv (XW-446) CD28-CD3ζ CAR, pCDCAR1 Human XW-446 Human 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF9613 TS-IL15 SA Anti-Human GD2 scFv (XW-447) CD28-CD3ζ CAR, pCDCAR1 Human XW-447 Human 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF9614 TS-IL15 SA Anti-Human GD2 scFv (XW-448) CD28-CD3ζ CAR, pCDCAR1 Human XW-448 Human 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0822-YF9615 TS-IL15 SA Anti-Human GD2 scFv (XW-449) CD28-CD3ζ CAR, pCDCAR1 Human XW-449 Human 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ Lentiviral vector   Add to Cart   Datasheet
XS-0823-LX51 Anti-hGD2 (2A) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector Human 2A Adenoviral vectors   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.